GE HealthCare Third Quarter 2026 Earnings Conference Call - GE HEALTHCARE TECHNOLOGIES INC

Financial Performance:

• Third quarter revenue reached $5.5 billion, reflecting 6.2% organic growth and 6.7% reported growth in products, supported by an 8.1% increase in service revenue.
• Organic orders grew 4% for the quarter, with a trailing 12-month organic order growth of 4.6%; book-to-bill ratio stood at 1.03.
• Backlog increased by $2.5 billion (12% YoY) to $23.7 billion, indicating strong future visibility.
• Adjusted EBIT margin expanded 180 basis points year-over-year to 16.6%, driven by volume, pricing, reduced tariffs, and cost mitigation actions.
• Adjusted EPS rose 25.1% to $1.34 per share.
• Free cash flow totaled $793 million, up $310 million YoY, bolstered by lower tariff payments, operational profitability, and favorable collection timing.

Guidance and Future Outlook:

• Full-year 2026 organic revenue growth guidance raised to approximately 4%.
• Adjusted EBIT margin guidance raised to 15.5%–15.7% (up from prior guidance).
• Adjusted EPS guidance increased to $4.95–$5.05.
• Full-year free cash flow guidance raised to exceed $1.6 billion.
• Adjusted effective tax rate expected between 20%–21%.
• Management anticipates a forward exchange tailwind of approximately 75 basis points.
• Q4 outlook implies 3%–4% growth, primarily driven by Advanced Imaging Solutions (AIS) and Pharmaceutical Diagnostics (PDX), while Patient Care Solutions (PCS) faces a base effect from a prior year product hold release.

Business Segments and Product Lines:

• Advanced Imaging Solutions (AIS): Organic revenue grew 4.5%; margin expanded 130 basis points driven by strength in CT, cardiovascular, and surgical innovations.
• Pharmaceutical Diagnostics (PDX): Delivered robust 13.8% organic revenue growth; segment EBIT margin reached 29.9% (up 50 bps), supported by contrast media and radiopharmaceuticals.
• Patient Care Solutions (PCS): Achieved 8.8% organic revenue growth with significant sequential margin expansion (480 bps) due to improved operational execution and supply chain resolution.
• Product Launches: Received CE marking for Photonova Spectra (photon-counting CT); StarGuide GX pending FDA clearance; expanded ultrasound platforms in cardiovascular, women's health, and general imaging.
• Strategic Acquisition: Announced plans to acquire Sophie Biosciences to establish a "final mile" US PET radiopharmaceutical supply footprint and strengthen the pipeline with FAPI 74.
• Leadership: Jeanette Bankas stepped down as head of PCS; Neil Sandy, current head of product strategy, appointed as CEO of PCS.

Market and Competitive Landscape:

• PDX business has delivered high single-digit growth for five consecutive quarters, capitalizing on precision medicine trends in oncology, cardiology, and neuro.
• Strong demand observed for AI-enabled CT solutions, MR upgrades, and cardiovascular ultrasound, with the pipeline for new equipment orders at record levels.
• China market showing recovery with 7% revenue growth in Q3, aided by positive FX impacts and stabilizing tender activity despite Value-Based Procurement (VBP) pressures.
• General imaging ultrasound market viewed as attractive; GE Healthcare maintains a strong position with its "Logic" platform amidst competitor disruptions (e.g., Siemens pullback, Philips recalls).
• The "OmniFay" generic market remains competitive with existing players; management expects new entrants to absorb industry demand rather than significantly erode GE's share.

Risks and Challenges:

• Inflationary pressures on memory chips and oil prices continued to impact margins, though partially offset by mitigation strategies.
• Supply chain resiliency remains a focus due to cross-industry demand for advanced computing components (memory chips); multi-year agreements secured with partners to ensure supply.
• Tariff uncertainty persists, specifically regarding Section 232; management is hedging via pricing, cost productivity, and supply chain localization.
• PCS segment faced prior supply constraints that required intense operational focus to resolve.
• Macro headwinds regarding capital equipment spending cycles, though management reports no material slowdown in scan data or contrast use.

Management Commentary and Tone:

• Tone is confident and optimistic, citing "strong momentum" and "execution" as key drivers for raising guidance.
• CEO Peter Arduini highlighted the success of the "Heartbeat" operating system in driving operational simplification, SQDCI (Safety, Quality, Delivery, Cost, Innovation), and backlog conversion.
• New CFO Bill Grogan expressed high confidence in the company's culture, technology portfolio, and growth opportunities, noting strong alignment with management's previous observations.
• Management emphasized the strategic value of the PDX "d3" model (drugs, devices, data) and the recurring revenue nature of radiopharmaceuticals.

Analyst Questions and Answers:

• CapEx & China: Analysts questioned capital budget trends and China growth; management confirmed strong customer surveys, no visible slowdown in procedures, and improving tender consistency in China.
• Backlog Volatility: Regarding lower book-to-bill (1.03), management attributed this to "lumpiness" of large deals and a strong prior-year base, not market weakness, citing a robust order pipeline.
• Fercoato Growth: Discussion on the ramp to $500M annualized revenue for Fercoato by 2028; management confirmed strong momentum and broad-based adoption as SPECT users convert to PET.
• Memory Chips: Addressed securing supply chains against AI/data center demand for memory chips; confirmed favored-nation status and pricing agreements with partners.
• Q4 & 2027 Outlook: Clarified that implied Q4 growth reflects PCS base effects rather than deceleration; 2027 outlook remains positive with continued top-line momentum and margin expansion expected from new product mix.
• Ultrasound: Reaffirmed commitment to general imaging ultrasound, noting it as a critical global platform and a beneficiary of competitor supply issues.
• Sophie Acquisition: Confirmed acquisition will not delay strategic review for PCS; acquisition aims to secure supply chain for short-lived radiopharmaceuticals and enhance future theranostics capabilities.

Other Key Points:

• GE Healthcare will showcase new AI-enabled, department-level integrated products at the upcoming RSNA (Radiological Society of North America) conference.
• Services segment achieved standardized digital support improvements, expecting to save ~10,000 hours of field time for CT, MR, and X-ray via first-visit resolutions.
• Cash dividend increased by 14% in the quarter.
• The "Heartbeat" methodology has shifted PCS operations from weekly to daily management cadences, addressing supply gaps and improving delivery.